{"id":635551,"date":"2026-03-09T10:41:43","date_gmt":"2026-03-09T14:41:43","guid":{"rendered":"https:\/\/www.singlecare.com\/blog\/?p=635551"},"modified":"2026-03-09T10:41:43","modified_gmt":"2026-03-09T14:41:43","slug":"flovent-generic","status":"publish","type":"post","link":"https:\/\/www.singlecare.com\/blog\/news\/flovent-generic\/","title":{"rendered":"FDA approves first true generic of Flovent inhaler"},"content":{"rendered":"

The Food and Drug Administration (FDA) has approved the first true generic of Flovent HFA (fluticasone propionate), an inhaled medication used as a maintenance treatment of asthma in people ages 4 years and older. The FDA has approved the generic in the 44 mcg per actuation strength.\u00a0<\/span><\/p>\n

Asthma <\/span><\/a>affects more than 28 million people in the U.S., according to the Asthma and Allergy Foundation of America (AAFA), and <\/span>inhaled corticosteroids<\/span><\/a> like <\/span>fluticasone propionate<\/span><\/a> are considered a lifeline for many.\u00a0<\/span><\/p>\n

That\u2019s because inhaled corticosteroids are considered highly effective in preventing asthma exacerbations in people with persistent asthma, reducing symptoms and improving quality of life.\u00a0<\/span><\/p>\n

Why this approval is significant<\/span><\/h2>\n

Authorized generics<\/span><\/a> of this medication have been available, but the approval of this generic version of <\/span>fluticasone propionate<\/span><\/a> marks the first independently manufactured generic approved through the FDA\u2019s abbreviated pathway.<\/span><\/p>\n

That\u2019s significant because it may ultimately result in cost savings for people who need this type of medication. True generics can drive price competition in ways that authorized generics might not.\u00a0<\/span><\/p>\n

In the approval announcement released on March 3, the FDA noted that granting approval of fluticasone propionate inhalation aerosol to Glenmark Specialty SA will give people more options and expand access to affordable asthma treatment.<\/span><\/p>\n

\u201cBetween 5 and 10% of Americans and just over 6% of children have an asthma diagnosis. Flovent is a highly effective preventive medication, which, when used regularly, has been linked to a reduction in asthma-related hospitalizations and admissions to intensive care. As of today, with the approval of the first generic metered dose inhaler form of the medication, we anticipate increased availability and reduced costs of treating this prevalent and at times very serious condition,\u201d Tracy Beth H\u00f8eg, MD, Ph.D, acting director of the FDA’s Center for Drug Evaluation and Research, said in a<\/span> statement<\/span><\/a>.<\/span><\/p>\n

What happened to brand-name Flovent<\/span><\/h2>\n

The news of the approval of the first true generic fluticasone propionate inhalation aerosol comes more than two years after manufacturer GlaxoSmithKline (GSK) announced it would stop producing the brand-name Flovent on January 1, 2024.<\/span><\/p>\n

Until then, GSK had produced both a metered dose inhaler (Flovent HFA) and a dry powder inhaler (Flovent Diskus). When brand-name <\/span>Flovent was discontinued<\/span><\/a>, patients had to decide whether to switch to a different asthma medication or move to an authorized generic.\u00a0<\/span><\/p>\n

For example, their healthcare provider may have considered <\/span>other inhaled corticosteroids<\/span><\/a> on the market, which include <\/span>alternatives<\/span><\/a> such as:\u00a0<\/span><\/p>\n